Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 66

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 66
---
 the Successor for the nine months period ended September 30, 2025, the Predecessor for the period commencing January 1
through July 23, 2024 and Successor for the period commencing July 24 through September 30, 2024.

|                                     |     |     Successor |       |   |     |                |     |   |     |    Predecessor |       |
|                                     |     |  For the Nine 
  months ended 
 September 30, |       |   |     | For the period 
     commencing 
        July 24 
        through 
  September 30, |     |   |     | For the period 
     commencing 
      January 1 
        through 
       July 23, |       |
|                                     |     |          2025 |       |   |     |           2024 |     |   |     |           2024 |       |
| Operating expenses                  |     |               |       |   |     |                |     |   |     |                |       |
| Research and development expenses   |     |               |   835 |   |     |                | 331 |   |     |                | 1,162 |
| General and administrative expenses |     |               | 1,423 |   |     |                | 464 |   |     |                |   257 |
| Operating loss                      |     |               | 2,258 |   |     |                | 795 |   |     |                | 1,419 |
| Financial income, net               |     |               |   (68 | ) |     |                | (25 | ) |     |                |     2 |
| Net loss and comprehensive loss     |     |               | 2,190 |   |     |                | 770 |   |     |                | 1,421 |

<div align='center'>38</div>

Research and Development Expenses

Successor’s research and development
expenses totaled $835 thousand for the nine months period ended September 30, 2025, representing a decrease of $658 thousand, or 44.1%,
compared to Predecessor’s and successors’ combined $1,493 thousand for the same period. The research and development expenses comprise
mainly from salaries and related expenses, from share based payment expenses and other expenses. The decrease was mainly due to lower
share based payment expense